(MedPage Today) — The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday.
Approval stipulates use of the combination, with or without bevacizumab, in adults…
Source link : https://www.medpagetoday.com/hematologyoncology/ovariancancer/119831
Author :
Publish date : 2026-02-10 22:32:00
Copyright for syndicated content belongs to the linked Source.
